An Open-label, Non-comparative, Multi-centre Study to Assess the Efficacy and Safety of Bicalutamide When Used in Combination With Anastrozole for the Treatment of Gonadotropin-independent Precocious Puberty in Boys With Testotoxicosis

Trial Profile

An Open-label, Non-comparative, Multi-centre Study to Assess the Efficacy and Safety of Bicalutamide When Used in Combination With Anastrozole for the Treatment of Gonadotropin-independent Precocious Puberty in Boys With Testotoxicosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Bicalutamide (Primary) ; Anastrozole
  • Indications Precocious puberty
  • Focus Therapeutic Use
  • Acronyms BATT
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Nov 2017 Planned End Date changed from 11 Aug 2017 to 11 Dec 2017.
    • 22 Jun 2012 Planned number of patients is 20 as reported by EudraCT record.
    • 22 Jun 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2004-000384-10).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top